Background: Despite aggressive treatment, the mortality rate of cardiogenic shock with acute myocardial infarction (AMI) is high. We performed extracorporeal membrane oxygenation (ECMO) prior to coronary reperfusion, and evaluated the early clinical results and risk factors. Materials and Methods: From May 2006 to November 2009, we reviewed the medical records of 20 patients in cardiogenic shock with AMI (mean age 67.7±11.7 yrs, M : F 14 : 6). After initially performing ECMO using the CAPIOX emergency bypass system (EBS Ⓡ Terumo, Tokyo, Japan), patients underwent coronary reperfusion (coronary artery bypass grafting, 13; percutaneous coronary intervention, 7).
INTRODUCTION
The mortality rate of cardiogenic shock due to acute myocardial infarction (AMI) is as high as 60∼80% and may be higher without aggressive treatment. Besides the classical medical treatment, circulatory supportive devices such as the Intra Aortic Balloon Pump (IABP) and Ventricular Assistance Device (VAD) may be helpful [1] [2] [3] [4] [5] . Recently ECMO has Eui Suk Chung, et al − 274 − been adapted to the percutaneous approach and the self-charging system, so that it can support the whole body and coronary circulation fast, and has shown good clinical results in patients experiencing cardiogenic shock due to AMI [6] [7] [8] [9] . On the other hand, there is controversy about which procedure should be first, coronary reperfusion or ECMO, for cardiogenic shock due to AMI. Therefore, the authors have reviewed the short-term results of patients who had received ECMO just before coronary reperfusion in cases of cardiogenic shock due to AMI.
MATERIALS AND METHODS
We retrospectively reviewed 20 
RESULTS
The mean cannular insertion time for ECMO application We analyzed the risk factors related to death before ECMO and after ECMO. CPR time before ECMO (＞20 min), left ventricular ejection fraction (＜40%) before ECMO, and concentration of albumin (＜3.0 g/dL) were related to death (p＜ 0.05). ECMO support time (＞4.5 days), increase of Troponin I (＞100 ng/mL), ARF, DIC, and complications such as bleeding were also related to the death (p＜0.05, Table 2, 3) .
DISCUSSION
Circulatory supporting devices such as IABP and VAD limit the effect of cardiogenic shock due to AMI. IABP is fast and easy to apply and increases coronary blood flow.
However, its effectiveness could be reduced in cases of cardiac arrest or ventricular arrhythmia [1, 2] . VAD can also be effective, but requires an additional surgical procedure, more time, and money, and is therefore unsuitable in case of an emergency. Recently, VAD that can be applied percutaneously has become available. However, additional equipment and procedures are required in order to apply a VAD [10] .
Since the advent of the percutaneous approach for ECMO, it has shown good results and that it can be applied relatively reported similar results [11, 12] .
There has been debate about whether coronary reperfusion or ECMO support should be first applied first at the time of postinfarct cardiogenic shock. In most cases, there has been limited application of ECMO after medical treatment and coronary reperfusion with IABP support at the time of cardiogenic shock due to AMI [13] . However, in the high risk group, maintaining coronary and whole body circulation through aggressive cardiopulmonary circulatory support is helpful in advance. ECMO and the survival rate were 100% and 80%, respectively, in patients who underwent coronary reperfusion after ECMO support [15] . In Korea, Rhee et al. [7] and Ryu et
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− 277 − al. [8] reported the results of ECMO support before and after coronary reperfusion in ischemic heart disease, however, there has been no report of ECMO support just before coronary reperfusion. In this study, we performed ECMO on high risk patients who had cardiogenic shock and identified an ECMO weaning rate of 70% and a survival rate of 50%, which were similar results to those of several previous studies.
There Short term results are usually satisfactory after discharge.
Studies have reported no differences in survival rates between
immediately following discharge and one year after discharge.
This study also showed no deaths immediately after discharge, and a good clinical course in all cases [11, 20] .
CONCLUSION
In this study, we analyzed the short-term results and risk factors related to death when ECMO support was applied before coronary reperfusion therapy in cases of postinfarct cardiogenic shock. Study limitations include a small study group, retrospective study, and the possibility of selection bias from nonrandomized study design. Coronary reperfusion therapy after ECMO support showed clinically significant results and good short-term results after discharge. In the high risk group, early ECMO support before coronary reperfusion procedures, correction of risk factors, and minimization of complications would result in improved clinical results for cardiogenic shock due to AMI. Long-term clinical applications of ECMO require further study.
